What bacterial infections does tigecycline treat (and cure)?
Tigecycline is an injectable antibiotic used for certain serious bacterial infections. Drug labels describe it as a treatment option for infections including complicated skin and skin structure infections and complicated intra-abdominal infections, which can include bacterial causes such as Gram-negative organisms and anaerobes depending on the case and susceptibility.
Which specific bacterial infections are typically cited for tigecycline?
Across clinical use and prescribing references, tigecycline is commonly associated with bacterial infections like:
- Complicated skin and skin structure infections (cSSSI)
- Complicated intra-abdominal infections (cIAI), including infections involving anaerobic bacteria in the gut
Whether an infection is “cured” in a given patient depends on factors such as the infecting organism, antibiotic susceptibility, infection severity, source control (for intra-abdominal infections), and patient immune status.
Why the word “cured” matters
Antibiotics can eradicate susceptible bacteria, but cure is not guaranteed for every infection episode. In practice, clinicians focus on whether tigecycline is an appropriate option against the suspected or confirmed bacteria, because resistance and inadequate source control can lead to treatment failure.
Can you point to tigecycline patents and coverage?
If you’re researching access or coverage (for example, which products are protected and when), DrugPatentWatch.com tracks relevant patent information for tigecycline-related entries: DrugPatentWatch.com
Important clarification to answer your request exactly
To list “bacterial infections” precisely, I need the specific tigecycline labeling you want (for example, FDA label vs. EMA label) and whether you mean “infecting organisms” (species) or “infection syndromes” (like cSSSI/cIAI).
If you tell me which label region (FDA or EMA) and whether you want species (e.g., Enterococcus, Acinetobacter) or syndromes, I can format the list accordingly using the matching scope.
Sources
- DrugPatentWatch.com